Tone mix
Week by week 51 weeks
Share of Dyne Therapeutics, Inc. Common Stock's 156 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Dec 29, 2025 · tone -100Dyne Therapeutics (NASDAQ:DYN) Cut to Sell at Wall Street Zen-153
- Week of Sep 28, 2026 · tone +99Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)+99
- Week of Aug 10, 2026 · tone +99Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH+81
- Week of Aug 4, 2025 · tone +100Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)+80
- Week of Jun 1, 2026 · tone +100Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)+73
- Week of Sep 8, 2025 · tone +100Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating+71
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Dyne Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 3 | +5 |
| Last 30 sessions | 7 | +31 |
| Last 90 sessions | 36 | +13 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
2 headlines, average tone +8: 1 positive, 0 neutral and 1 negative. Showing all 2.
- www.rttnews.com · 1 outletDyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 MilestonesPositive
- www.rttnews.com · 1 outletDyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028Negative
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones | www.rttnews.com | 1 | Positive |
| Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028 | www.rttnews.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 9, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletInsider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases $40,000.00 in StockNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases $40,000.00 in Stock | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 5, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletDyne Therapeutics' (DYN) Buy Rating Reiterated at Chardan CapitalPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Dyne Therapeutics' (DYN) Buy Rating Reiterated at Chardan Capital | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Dyne Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.